News
We send the latest information from SMC Laboratories.
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the …
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b…
TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first…
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detai…
Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a …
Lipocine announces positive topline Phase 2 results from LPCN1144 ongoing Lift study in biopsy-confirmed NASH subjects
Lipocine (USA, UA) announced on 12 January, 2021, positive topline Phase 2 results from LPCN1144 ongoing LiFT …
Chemomab announces positive Phase Ib results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd.(Israel) announced on 5 January, 2021, positive Phase Ib results of its SPARK study testing CM-10…
Can-Fite reports on progress with its Namodenoson NASH program
Can-Fite (Israel) reports on 14 December, 2020, on progress with its Namodenoson NASH program. For deta…
CytoDyn announces first patient enrolled in Phase 2 study for NASH
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 …